Pharming Group (PHAR) Expected to Announce Earnings on Thursday

Pharming Group (NASDAQ:PHARGet Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Pharming Group to post earnings of $0.07 per share and revenue of $76.67 million for the quarter.

Pharming Group Price Performance

Shares of PHAR opened at $8.86 on Thursday. The stock has a market capitalization of $602.75 million, a P/E ratio of -34.08 and a beta of -0.10. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.94. The company has a 50 day moving average of $9.25 and a 200-day moving average of $8.56. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Jefferies Financial Group started coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.

Get Our Latest Stock Analysis on PHAR

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Recommended Stories

Earnings History for Pharming Group (NASDAQ:PHAR)

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.